IT SOUNDS like science fiction, and for years it seemed as though it was just that: fiction.
But the idea of gene therapy—introducing copies of healthy genes into people who lack them, to treat disease—is at last looking as if it may become science fact.
The field got off to a bad start, with the widely reported death of an American liver patient in 1999. In 2003 some French children who were being treated with it for an immune-system problem called SCID developed leukaemia. Since then, though, things have improved. Indeed one procedure, for lipoprotein lipase deficiency (which causes high levels of blood fats, with all the problems those can bring), has been approved, in Europe, for clinical use.
The most recent success, announced last month in the Lancet, was of an experimental treatment for choroideremia, a type of blindness. This is caused by mutation of the gene for a protein called REP1. Without REP1, the eye’s light receptors degenerate. Robert MacLaren of Oxford University used a virus to deliver working versions of the REP1 gene to the most light-sensitive part of the retina. Five of the six participants in the trial duly experienced an improvement in their sensitivity to light. Two were so improved that they could read more letters than previously on a standard eye chart.
Dr MacLaren’s work complements that of Albert Maguire and Jean Bennett at the University of Pennsylvania, who use gene therapy to treat another eye disease, Leber’s congenital amaurosis. A defective version of a gene called RPE65 means that, in this condition, retinal cells are starved of vitamin A, which also causes blindness. Putting normal copies of RPE65 into the retina leads, as with REP1, to greater light sensitivity and—sometimes—clearer vision.
The Latest on: Gene therapy
[google_news title=”” keyword=”Gene therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene therapy
- Rocket Pharmaceuticals' Promising Path In Gene Therapyon March 1, 2024 at 2:03 pm
Rocket Pharmaceuticals' stock surged 76% following positive Phase 2 trial results for RP-A501. Read why RCKT is recommended a buy, for its unique market position.
- Positive Outlook for uniQure Backed by Strong Gene Therapy Pipeline and Strategic Advancementson March 1, 2024 at 9:05 am
H.C. Wainwright analyst Patrick Trucchio has maintained their bullish stance on QURE stock, giving a Buy rating on February 28. Patrick ...
- Optimistic Outlook for RegenXBio’s Gene Therapy Pipeline and Regulatory Prospects Spurs Buy Ratingon February 29, 2024 at 10:16 pm
Robert W. Baird analyst Brian Skorney maintained a Buy rating on RegenXBio (RGNX – Research Report) on February 27 and set a price target ...
- Accelerating Progress in Cell and Gene Therapyon February 29, 2024 at 4:00 pm
The remarkable advancements in cell and gene therapy (CGT) have ushered in a new era of medical possibilities, with the recent FDA approval of the first CRISPR therapy for sickle cell gene editing ...
- Novel Gene Editing Tool Improves Immune Cell Activityon February 29, 2024 at 8:00 am
Jennifer Doudna and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in gene editing. The gene editing techn | Immunology ...
- Sarepta’s Duchenne Gene Therapy Elevidys Nabs $200M on Strong Demandon February 29, 2024 at 6:19 am
Sarepta Therapeutics on Wednesday called the launch of the gene therapy for Duchenne muscular dystrophy “exceptional” but the company does not expect to see significant growth in the first half of ...
- Why Cell And Gene Therapy Design Processes Need More Efficient Quality Controlson February 29, 2024 at 3:00 am
Drugmakers must make the entire drug testing and quality control process as efficient and innovative as the drug discovery method itself.
- The Fight to Pay for Gene Therapyon February 29, 2024 at 2:01 am
There is new hope for seemingly incurable diseases, but the treatments will be truly revolutionary only if they are available to everyone.
- ‘Bad’ cholesterol gene silenced without altering the DNA sequenceon February 28, 2024 at 11:30 pm
By silencing the gene responsible for regulating ‘bad’ cholesterol without altering the primary DNA sequence, researchers have shown that it’s possible to use epigenetic editing to treat diseases ...
- Operational risks with gene therapies should improve with time, exec sayson February 28, 2024 at 1:09 am
With gene therapy programs, it is challenging to maintain the balancing act between the benefit and risk of a given indication, explained Nolan Townsend, CEO of Lexeo Therapeutics. Townsend was ...
via Bing News